Biotek-snakken — August 2024
-
FDA, de amerikanske sundhedsmyndigheder, har mandag sagt god for, at det danske biotekselskab Ascendis Pharma må sælge og markedsføre lægemidlet Yorvipath til behandling af kronisk hypoparathyroidisme hos voksne i USA. https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-yorvipathr-palopegteriparatide-first-and-only
-
Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001
· The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private
News Powered by Cision (news.cision.com)
-
Cessatech trykker på frem mod den amerikanske lancering og sikrer sig nu et større lån til markedsføringen af deres første produ
kt. Samtidig understreger de også forventningen om at se omsætning allerede i 2024. For mit vedkommende kan vi godt sige tak for en fin sommer og lad endelig efterår og vinter banke på døren nu
-
-
2 Biotech Stocks To Watch In August 2024 https://proinvestor.com/investornyt/1200034/2-biotech-stocks-to-watch-in-august-2024
-
Godmorgen
-
Bioporto går travlt andet halvår i møde: Lanceringer, partnerskaber og nyretest i fokus https://proinvestor.com/investornyt/1200639/bioporto-gar-travlt-andet-halvar-i-mode-lanceringer-partnerskaber-og-nyretest-i-fokus
-
Hej.
-
Erder
-
Har nogen herinde kendskab til Bactiquant?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind